Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease

Movement Disorders

Volumn 29, Issue 4, 2014, Pages 454-462

  Berg, Daniela ^a   Postuma, Ronald B ^b   Bloem, Bastiaan ^c   Chan, Piu ^d   Dubois, Bruno ^e   Gasser, Thomas ^a   Goetz, Christopher G ^f   Halliday, Glenda M ^g   Hardy, John ^h   Lang, Anthony E ⁱ   Litvan, Irene ^j   Marek, Kenneth ^k   Obeso, José ^l   Oertel, Wolfgang ^m   Olanow, C Warren ⁿ   Poewe, Werner ^o   Stern, Matthew ^p   Deuschl, Günther ^q  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b MONTREAL GENERAL HOSPITAL   (Canada)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d CAPITAL MEDICAL UNIVERSITY   (China)

^e PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^f RUSH UNIVERSITY MEDICAL CENTER   (United States)

^g UNIVERSITY OF NEW SOUTH WALES   (Australia)

^h UNIVERSITY COLLEGE LONDON   (United Kingdom)

ⁱ UNIVERSITY OF TORONTO   (Canada)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k INSTITUTE FOR NEURODEGENERATIVE DISORDERS   (United States)

^l UNIVERSITY OF NAVARRA   (Spain)

^m PHILIPPS UNIVERSITY MARBURG   (Germany)

ⁿ MOUNT SINAI HOSPITAL   (United States)

^o INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^p Penn Neurological Institute   (United States)

^q UNIVERSITY OF KIEL   (Germany)

more..

Author keywords

Disease heterogeneity; Gold standard; MDS diagnostic criteria; Nonmotor prodrome; Redefinition of PD; Subtypes

Indexed keywords

PARKIN; SYNUCLEIN;

ARTICLE; CLINICAL EXAMINATION; CLINICAL FEATURE; DEMENTIA; GOLD STANDARD; HEALTH CARE; HUMAN; LEWY BODY; MOTOR DYSFUNCTION; PARKINSON DISEASE; PREVALENCE; PRIORITY JOURNAL; PRODROMAL SYMPTOM; ADVISORY COMMITTEE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; NEUROPSYCHOLOGICAL TEST; PATHOLOGY;

ADVISORY COMMITTEES; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; HUMANS; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE;

EID: 84898057951     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25844     Document Type: Article

References (63)

1. Wider C, Dickson DW, Wszolek ZK. Leucine-rich repeat kinase 2 gene-associated disease: redefining genotype-phenotype correlation. Neurodegener Dis 2010;7:175-179.
2. Poulopoulos M, Levy OA, Alcalay RN. The neuropathology of genetic Parkinson's disease. Mov Disord 2012;27:831-842.
3. Beach TG, Adler CH, Sue LI, et al. Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol 2010;119:689-702.
4. Parkkinen L, Pirttila T, Alafuzoff I. Applicability of current staging/categorization of alpha-synuclein pathology and their clinical relevance. Acta Neuropathol 2008;115:399-407.
5. Dickson DW, Fujishiro H, Delledonne A, et al. Evidence that incidental Lewy body disease is pre-symptomatic Parkinson's disease. Acta Neuropathol 2008;115:437-444.
6. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197-211.
7. Orimo S, Takahashi A, Uchihara T, et al. Degeneration of cardiac sympathetic nerve begins in the early disease process of Parkinson's disease. Brain Pathol 2007;17:24-30.
8. Milber JM, Noorigian JV, Morley JF, et al. Lewy pathology is not the first sign of degeneration in vulnerable neurons in Parkinson disease. Neurology 2012;79:2307-2314.
9. Cheng HC, Ulane CM, Burke RE. Clinical progression in Parkinson disease and the neurobiology of axons. Ann Neurol 2010;67:715-725.
10. Wirdefeldt K, Gatz M, Schalling M, Pedersen NL. No evidence for heritability of Parkinson disease in Swedish twins. Neurology 2004;63:305-311.
11. Tanner CM. Is the cause of Parkinson's disease environmental or hereditary? Evidence from twin studies. Adv Neurol 2003;91:133-142.
12. Zimprich A, Biskup S, Leitner P, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004;44:601-607.
13. Marras C, Lohmann K, Lang A, Klein C. Fixing the broken system of genetic locus symbols: Parkinson disease and dystonia as examples. Neurology 2012;78:1016-1024.
14. McKeith I. Commentary: DLB and PDD: the same or different? Is there a debate? Int Psychogeriatr 2009;21:220-224.
15. Dubois B, Burn D, Goetz C, et al. Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force. Mov Disord 2007;22:2314-2324.
16. Lippa CF, Duda JE, Grossman M, et al. DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology 2007;68:812-819.
17. Dugger BN, Boeve BF, Murray ME, et al. Rapid eye movement sleep behavior disorder and subtypes in autopsy-confirmed dementia with Lewy bodies. Mov Disord 2012;27:72-78.
18. Klein JC, Eggers C, Kalbe E, et al. Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo. Neurology 2010;74:885-892.
19. Watson R, Blamire AM, Colloby SJ, et al. Characterizing dementia with Lewy bodies by means of diffusion tensor imaging. Neurology 2012;79:906-914.
20. Postuma RB, Gagnon JF, Vendette M, Montplaisir JY. Idiopathic REM sleep behavior disorder in the transition to degenerative disease. Mov Disord 2009;24:2225-2232.
21. Johansen KK, White LR, Sando SB, Aasly JO. Biomarkers: Parkinson disease with dementia and dementia with Lewy bodies. Parkinsonism Relat Disord 2010;16:307-315.
22. Goldman JG, Goetz CG, Brandabur M, Sanfilippo M, Stebbins GT. Effects of dopaminergic medications on psychosis and motor function in dementia with Lewy bodies. Mov Disord 2008;23:2248-2250.
23. McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005;65:1863-1872.
24. Marras C, Lang A. Parkinson's disease subtypes: lost in translation? J Neurol Neurosurg Psychiatry 2013;84:409-415.
25. van Rooden SM, Colas F, Martinez-Martin P, et al. Clinical subtypes of Parkinson's disease. Mov Disord 2011;26:51-58.
26. van Rooden SM, Heiser WJ, Kok JN, Verbaan D, van Hilten JJ, Marinus J. The identification of Parkinson's disease subtypes using cluster analysis: a systematic review. Mov Disord 2010;25:969-978.
27. Reijnders JS, Ehrt U, Lousberg R, Aarsland D, Leentjens AF. The association between motor subtypes and psychopathology in Parkinson's disease. Parkinsonism Relat Disord 2009;15:379-382.
28. Post B, Speelman JD, de Haan RJ. Clinical heterogeneity in newly diagnosed Parkinson's disease. J Neurol 2008;255:716-722.
29. Lewis SJ, Foltynie T, Blackwell AD, Robbins TW, Owen AM, Barker RA. Heterogeneity of Parkinson's disease in the early clinical stages using a data driven approach. J Neurol NeurosurgPsychiatry 2005;76:343-348.
30. Graham JM, Sagar HJ. A data-driven approach to the study of heterogeneity in idiopathic Parkinson's disease: identification of three distinct subtypes. Mov Disord 1999;14:10-20.
31. Schrag A, Quinn NP, Ben-Shlomo Y. Heterogeneity of Parkinson's disease. J Neurol Neurosurg Psychiatry 2006;77:275-276.
32. Selikhova M, Williams DR, Kempster PA, Holton JL, Revesz T, Lees AJ. A clinico-pathological study of subtypes in Parkinson's disease. Brain 2009;132:2947-2957.
33. Suchowersky O, Reich S, Perlmutter J, Zesiewicz T, Gronseth G, Weiner WJ. Practice parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006;66:968-975.
34. Marras C, Rochon P, Lang AE. Predicting motor decline and disability in Parkinson disease: a systematic review. Mov Disord 2002;59:1724-1728.
35. Post B, Merkus MP, de Haan RJ, Speelman JD. Prognostic factors for the progression of Parkinson's disease: a systematic review. Mov Disord 2007;22:1839-1851; quiz, 988.
36. Bohnen NI, Muller ML, Kotagal V, et al. Olfactory dysfunction, central cholinergic integrity and cognitive impairment in Parkinson's disease. Brain 2010;133:1747-1754.
37. Postuma RB, Bertrand JA, Montplaisir J, et al. Rapid eye movement sleep behavior disorder and risk of dementia in Parkinson's disease: a prospective study. Mov Disord 2012;27:720-726.
38. Romenets SR, Gagnon JF, Latreille V, et al. Rapid eye movement sleep behavior disorder and subtypes of Parkinson's disease. Mov Disord 2012;27:996-1003.
39. Wickremaratchi MM, Perera D, O'Loghlen C, et al. Prevalence and age of onset of Parkinson's disease in Cardiff: a community based cross sectional study and meta-analysis. J Neurol Neurosurg Psychiatry 2009;80:805-807.
40. Van Den Eeden SK, Tanner CM, Bernstein AL, et al. Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am J Epidemiol 2003;157:1015-1122.
41. Braak H, Del TK. Invited article: Nervous system pathology in sporadic Parkinson disease. Neurology 2008;70:1916-1925.
42. Ross GW, Petrovitch H, Abbott RD, et al. Association of olfactory dysfunction with risk for future Parkinson's disease. AnnNeurol 2008;63:167-173.
43. Abbott RD, Ross GW, Petrovitch H, et al. Bowel movement frequency in late-life and incidental Lewy bodies. Mov Disord 2007;22:1581-1586.
44. Berg D, Seppi K, Behnke S, et al. Enlarged substantia nigra hyperechogenicity and risk for Parkinson disease: a 37-month 3-center study of 1847 older persons. Arch Neurol 2011;68:932-937.
45. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988;51:745-752.
46. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 1999;56:33-39.
47. Koller WC. How accurately can Parkinson's disease be diagnosed? Neurology 1992;42(1 Suppl 1):6-16; discussion, 57-60.
48. Calne DB, Snow BJ, Lee C. Criteria for diagnosing Parkinson's disease. Ann Neurol 1992;32 Suppl:S125-S127.
49. Ward CD, Gibb WR. Research diagnostic criteria for Parkinson's disease. Adv Neurol 1990;53:245-249.
50. Rajput AH, Rozdilsky B, Rajput A. Accuracy of clinical diagnosis in parkinsonism-a prospective study. Can J Neurol Sci 1991;18:275-278.
51. Larsen JP, Dupont E, Tandberg E. Clinical diagnosis of Parkinson's disease. Proposal of diagnostic subgroups classified at different levels of confidence. Acta Neurol Scand 1994;89:242-251.
52. Aerts MB, Esselink RA, Post B, van de Warrenburg BP, Bloem BR. Improving the diagnostic accuracy in parkinsonism: a three-pronged approach. Pract Neurol 2012;12:77-87.
53. Velseboer DC, de Haan RJ, Wieling W, Goldstein DS, de Bie RM. Prevalence of orthostatic hypotension in Parkinson's disease: a systematic review and meta-analysis. Parkinsonism Relat Disord 2011;17:724-729.
54. Martinez-Martin P, Rodriguez-Blazquez C, Kurtis MM, Chaudhuri KR. The impact of non-motor symptoms on health-related quality of life of patients with Parkinson's disease. Mov Disord 2011;26:399-406.
55. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
56. Louis ED, Bennett DA. Mild parkinsonian signs: an overview of an emerging concept. Mov Disord 2007;22:1681-1688.
57. Buchman AS, Shulman JM, Nag S, et al. Nigral pathology and parkinsonian signs in elders without Parkinson disease. Ann Neurol 2012;71:258-266.
58. Uemura Y, Wada-Isoe K, Nakashita S, Nakashima K. Mild parkinsonian signs in a community-dwelling elderly population sample in Japan. J Neurol Sci 2011;304:61-66.
59. Lost D, Tang MX, Schupf N, Mayeux R. Functional correlates and prevalence of mild parkinsonian signs in a community population of older people. Arch Neurol 2005;62:297-302.
60. Buchman AS, Nag S, Shulman JM, et al. Locus coeruleus neuron density and parkinsonism in older adults without Parkinson's disease. Mov Disord 2012;27:1625-1631.
61. Hughes AJ, Daniel SE, Lees AJ. Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease. Neurology 2001;57:1497-1499.
62. Tolosa E, Wenning G, Poewe W. The diagnosis of Parkinson's disease. Lancet Neurol 2006;5:75-86.
63. Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 2002;125:861-870.